# Case report: Treatment with Phesgo® in a patient receiving hemodialysis

## TL;DR

This case report describes the first use of Phesgo® in a hemodialysis patient with breast cancer, showing some effectiveness without major side effects.

## Contribution

First published case of Phesgo® use in a hemodialysis patient with metastatic HER2-positive breast cancer.

## Key findings

- Partial response was achieved in the patient after 8 months of treatment.
- No significant toxicity was observed during the treatment period.
- The drug combination showed activity in a hemodialysis patient.

## Abstract

Patients with metastatic HER2-positive breast cancer have multiple therapeutic options. However, most are not studied in the renal replacement therapy (RRT) setting.

We report the use of Phesgo® (subcutaneous fixed-dose combination of trastuzumab and pertuzumab) combined with exemestane as a first-line treatment of metastatic HER2-positive breast cancer in a hemodialysis patient with multiple comorbidities. Partial response was attained, with disease progression after 8 months without evidence of significant toxicity.

This case report is, to our knowledge, the first published case documenting the use of Phesgo® in a hemodialysis patient. No new safety signs were seen, and activity was documented, adding support to the use of this drug combination in such a patient population.